Corcept Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Corcept Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Corcept Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Corcept Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Corcept Therapeutics Inc (Corcept) discovers, develops, and commercializes innovative medicines for the treatment of psychiatric, oncologic, and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome and prostate cancer; rosella and bella for ovarian cancer; dazals for ALS; and miricorilant for NASH and antipsychotic-induced weight gain. It also focuses on therapeutic areas such as diabetes, anxiety, antipsychotics, hypertension, obesity, addiction, non-small cell lung cancer, neurodegenerative diseases, osteoporosis, central serous chorioretinopathy, psychiatry, and metabolic-associated fatty liver disease or non-alcoholic fatty liver disease. Corcept is headquartered in Menlo Park, California, the US.
Headquarters
United States of America
Address
101 Redwood Shores Parkway, Redwood City, California, 94065
Website
www.corcept.com
Telephone
1 650 3273270
No of Employees
730
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CORT (NASD)
Revenue (2024)
$761.4M
12.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-29.4%
(2024 vs 2023)
Market Cap*
$9.5B
Net Profit Margin (2024)
XYZ
-37.4%
(2024 vs 2023)
* As of and is in US$
Corcept Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Korlym | Korlym |
| Pipeline: | |
| Relacorilant: Endogenous Cushing syndrome (GRACE), Hypercortisolism associated with adrenal adenoma or hyperplasia (GRADIENT), and an extension study to evaluate long-term safety | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In October, the company submitted a Marketing Authorization Application to the European Medicines Agency for relacorilant to treat patients with platinum-resistant ovarian cancer. |
| 2024 | Regulatory Approval | In March, the company received a New Drug Application (NDA) submission for its relacorilant from the US FDA. |
| 2022 | Official Trials/Tests | In June, the company initiated ROSELLA, a pivotal phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer. |
Competitor Comparison
| Key Parameters | Corcept Therapeutics Inc | Teva Pharmaceutical Industries Ltd | Recordati SpA | Acadia Pharmaceuticals Inc | Xeris Biopharma Holdings Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Israel | Italy | United States of America | United States of America |
| City | Redwood City | Tel Aviv | Milan | San Diego | Chicago |
| State/Province | California | Tel Aviv | - | California | Illinois |
| No. of Employees | 730 | 31,173 | 4,583 | 796 | 435 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James N. Wilson | Chairman | Executive Board | 1999 | 82 |
| Joseph K. Belanoff, M.D. | Chief Executive Officer; Director; President | Executive Board | 2014 | 68 |
| Atabak Mokari | Chief Financial Officer; Treasurer | Senior Management | 2021 | 49 |
| Hazel Hunt Ph.D. | Chief Scientific Officer | Senior Management | 2020 | 66 |
| Joseph D. Lyon | Chief Accounting and Technology Officer | Senior Management | 2024 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer